Insider Selling: Medpace (NASDAQ:MEDP) VP Sells $4,500,000.00 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) VP Susan Burwig sold 7,500 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president directly owned 62,984 shares of the company’s stock, valued at $37,790,400. The trade was a 10.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Trading Up 2.5%

MEDP stock traded up $14.52 during trading on Wednesday, reaching $585.49. 580,873 shares of the stock were exchanged, compared to its average volume of 364,017. The firm’s 50 day moving average is $498.48 and its 200 day moving average is $493.41. The firm has a market cap of $16.34 billion, a P/E ratio of 34.32, a price-to-earnings-growth ratio of 2.63 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the previous year, the company posted $3.10 earnings per share. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MEDP. Barclays set a $600.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. BMO Capital Markets raised their price target on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. TD Cowen lifted their price target on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Two analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and an average target price of $584.18.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. AQR Capital Management LLC boosted its holdings in Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after purchasing an additional 324,293 shares during the last quarter. Wasatch Advisors LP grew its holdings in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after acquiring an additional 24,625 shares during the last quarter. Invesco Ltd. lifted its holdings in Medpace by 18.9% during the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Medpace by 8.3% in the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after purchasing an additional 38,760 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.